Allelic variant 6A (rs35068180) of the MMP-3 promoter region as a predictor of cardiotoxicity after the end of adjuvant chemotherapy with doxorubicin in patients with breast cancer

Aim. To evaluate the relationship of polymorphic variants rs2232228 of the HAS3 gene, rs8187710 of the ABCC2 gene, rs35068180 of the MMP-3 gene with cardiotoxicity after the end of adjuvant chemotherapy in patients with breast cancer.

Material and methods. The study included 100 patients (women, mean age 52,5±9,4 years) diagnosed with breast cancer who received anthracycline antibiotics (doxorubicin, total dose 240 mg/m² or 360 mg/m²). Echocardiography was performed before and after the end of chemotherapy. Polymorphic status of selected targets was determined using the real-time polymerase chain reaction.

Results. After the end of chemotherapy, based on the changes of left ventricular ejection fraction and global longitudinal strain, cardiotoxicity (CT) was detected in 20 patients. There were following significant differences between subgroups: rs8187710 of the ABCC2 gene — not identified; rs2232228 of the HAS3 gene — genotype AA, odds ratio (OR) 3,37 (95% confidence interval (CI) 1,14; 9,97) and allelic variant A, OR 2,17 (95% CI 0,98; 4,80) are significantly more common (p<0,05) in the cardiotoxicity+ subgroup; rs35068180 of the MMP-3 gene — genotype 6A/6A, OR 2,53 (95% CI 0,93; 6,88) and allelic variant 6A, OR 2,19 (95% CI 1,08; 4,44) are significantly more often (p<0,05) in the cardiotoxicity+ subgroup.

Conclusion. Genotype 6A/6A, allelic variant 6A rs35068180 of the MMP-3 gene, genotype AA and allelic variant A rs2232228 of the HAS3 gene can be considered as predictors of early cardiotoxicity after the end of chemotherapy in patients with breast cancer receiving doxorubicin.

1. Tantawy M, Pamittan FG, Singh S, et al. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity. Clin Transl Sci. 2021;14(1):36-46. doi:10.1111/cts.12857.

2. Abrahams С, Woudberg NJ, Lecour S. Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? Lipids Health Dis. 2022;21(1):85. doi:10.1186/s12944-022-01694-y.

3. Rawat PS, Jaiswal A, Khurana A, et al. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi:10.1016/j.biopha.2021.111708.

4. Siemens А, Rassekh SR, Ross CJD, et al. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity. Ther Drug Monit. 2023;45(3):337-44. doi:10.1097/FTD.0000000000001077.

5. Kuang Z, Wu J, Tan Y, et al. MicroRNA in the Diagnosis and Treatment of DoxorubicinInduced Cardiotoxicity. Biomolecules. 2023;13(3):568. doi:10.3390/biom13030568.

6. Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? Pharmacol Ther. 2016;168:113-25. doi:10.1016/j.pharmthera.2016.09.009.

7. Kuzheleva EA, Garganeeva AA, Tukish OV, et al. A review of potential predictors of anthracycline-induced cardiotoxicity from the perspective of the pathogenesis of the disease. Siberian Journal of Clinical and Experimental Medicine. 2022;37(3):19-28. (In Russ.) doi:10.29001/2073-8552-2022-37-3-19-28.

8. Yang X, Li G, Guan M, et al. Potential Gene Association Studies of ChemotherapyInduced Cardiotoxicity: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021;4;8:651269. doi:10.3389/fcvm.2021.651269.

9. Shi S, Chen Y, Luo Z, et al. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun Signal. 2023;14;21(1):61. doi:10.1186/s12964-023-01077-5.

10. Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol. 2014;32:647- 53. doi:10.1200/JCO.2013.50.3557.

11. Al-Otaibi TK, Weitzman B, Tahir UA, et al. Genetics of Anthracycline-Associated Cardiotoxicity. Front Cardiovasc Med. 2022;21;9:867873. doi:10.3389/fcvm.2022.867873.

12. Guizani I, Zidi W, Zayani Y, et al. Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study. Mol Biol Rep. 2022;49(10):9171-9. doi:10.1007/s11033-022-07742-1.

13. Munhoz FBA, Godoy-Santos AL, Santos MCLG. MMP-3 polymorphism: Genetic marker in pathological processes (Review). Mol Med Rep. 2010;3(5):735-40. doi:10.3892/mmr.2010.340.

14. Petrova EB, Popel ON, Shishko ON, et al. Dyslipidemia and atherosclerosis of the precerebral arteries in asymptomatic individuals with subclinical hypothyroidism. Cardiology in Belarus. 2023;15(3):333-43. (In Russ.) doi:10.34883/PI.2023.15.3.004.

15. Dempke WCM, Zielinski R, Winkler C, et al. Anthracycline-induced cardiotoxicity — are we about to clear this hurdle? Eur J Cancer. 2023;185:94-104. doi:10.1016/j.ejca.2023.02.019.

16. Wang Z, Fan Z, Yang L, et al. Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors. Front Cardiovasc Med. 2023;25;10:1014400. doi:10.3389/fcvm.2023.1014400.

17. Leong SL, Chaiyakunapruk N, Lee SW. Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Sci Rep. 2017;27;7(1):39. doi:10.1038/s41598-017-00075-1.

18. Huang XY, Han LY, Huang XD, et al. Association of Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3 Gene Variants with Ischemic Stroke and Its Subtype. J Stroke Cerebrovasc Dis. 2017;26(2):368-75. doi:10.1016/j.jstrokecerebrovasdis.2016.09.034.

19. Djuric T, Kuveljic J, Djordjevic A, et al. Association of MMP1 and MMP3 haplotypes with myocardial infarction and echocardiographic parameters of the left ventricle. Mol Genet Genomic Med. 2022;10(9):e2022. doi:10.1002/mgg3.2022.

20. Tang LJ, Chen XF, Zhu M, et al. Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem. 2007;40(18):1427-30. doi:10.1016/j.clinbiochem.2007.09.013.

21. Kopteva KV, Grakov EV, Shilov SN, et al. Anthracycline-induced cardiotoxicity: the role of genetic predictors. Kardiologiia. 2023;63(4):22-8. (In Russ.) doi:10.18087/cardio.2023.4.n1946.

22. Chernyak SV, Kovsh EV, Sevruk TV, et al. Prevention of early cardiotoxicity in the systemic treatment of resectable breast cancer. Cardiology in Belarus. 2023;15(2):193-203. (In Russ.) doi:10.34883/PI.2023.15.2.003.